Midostaurin is the 1st New and Approved AML Drug in a Long Time - For patients with FLT3 positive AML in the upfront setting

Midostaurin is the 1st New and Approved AML Drug in a Long Time - For patients with FLT3 positive AML in the upfront setting

User Photo
moasc

2 years
58 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Deepa Jeyakumar, MD, from UC Irvine Health talks about, Midostaurin, the 1st new and approved AML drug in a long time for patients with FLT3 positive AML in the upfront setting at MOASCs Spotlight On® Hematology in Huntington Beach.
Up Next Autoplay
User Photo